INNOVIVA, INC. Unrecognized Tax Benefits
INNOVIVA, INC. (INVA) had Unrecognized Tax Benefits of $62.71 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefits · last filed 2026-02-25
- 2025-12-31: Unrecognized Tax Benefits $62.71M.
- 2024-12-31: Unrecognized Tax Benefits $61.29M.
- 2023-12-31: Unrecognized Tax Benefits $19.44M.
- 2022-12-31: Unrecognized Tax Benefits $16.32M.
| Period end | Unrecognized Tax Benefits |
|---|---|
| 2025-12-31 | $62.71M 10-K · filed 2026-02-25 |
| 2024-12-31 | $61.29M 10-K · filed 2026-02-25 |
| 2023-12-31 | $19.44M 10-K · filed 2026-02-25 |
| 2022-12-31 | $16.32M 10-K · filed 2026-02-25 |
| 2021-12-31 | $14.87M 10-K · filed 2025-02-26 |
| 2020-12-31 | $15.19M 10-K/A · filed 2024-03-05 |
| 2019-12-31 | $15.34M 10-K · filed 2023-02-28 |
| 2018-12-31 | $15.41M 10-K/A · filed 2022-03-17 |
| 2017-12-31 | $15.49M 10-K · filed 2021-02-25 |
| 2016-12-31 | $15.49M 10-K · filed 2020-02-19 |
| 2015-12-31 | $15.49M 10-K · filed 2018-02-23 |
| 2014-12-31 | $15.46M 10-K · filed 2018-02-23 |
| 2013-12-31 | $57.42M 10-K · filed 2017-02-28 |
| 2012-12-31 | $52.50M 10-K · filed 2016-02-24 |
| 2011-12-31 | $46.90M 10-K · filed 2015-02-27 |
| 2010-12-31 | $42.60M 10-K · filed 2014-03-03 |
| 2009-12-31 | $39.60M 10-K · filed 2013-02-26 |
| 2008-12-31 | $36.20M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |